SGN-CD70A / Pfizer - LARVOL DELTA

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. (PubMed, Blood Adv) - "Most importantly, multiple-dosing of SGN-CD70A induced complete eradication of established tumors in PDXs measured by cfDNA. Our results demonstrated marked anti-tumor activity of SGN-CD70A in CTCL PDXs, providing compelling support for its clinical investigation."

Journal • Preclinical • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD70 • TNFA

[VIRTUAL] A CD70 antibody-drug conjugate is highly active and induces long term remission in patient-derived xenograft mouse models of cutaneous T cell lymphoma (AACR 2021) - "One week after tumor inoculation, mice were treated intraperitoneally with single-dosing of PBS, 100 μg/kg (SGN70A100) or 300 μg/kg (SGN70A300) of SGN-CD70A. Using CTCL PDX models, SGN-CD70A has marked anti-tumor activity, leading to long-term survival of treated mice. Our results provide a rationale for clinical investigation of SGN-CD70A in patients with TCL."

Preclinical • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD70

Seattle Genetics initiates phase 1 clinical trial of antibody-drug conjugate SGN-CD70A for non-Hodgkin lymphoma and renal cell carcinoma (Seattle Genetics Press Release) - P1, N=95; "Seattle Genetics...announced the initiation of a phase 1 clinical trial evaluating SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell carcinoma (RCC)....The phase 1 trial is designed to assess the safety and antitumor activity of SGN-CD70A....The primary endpoints are to estimate the maximum tolerated dose and to evaluate the safety of SGN-CD70A."

New P1 trial • Phase shift • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma

Seattle Genetics reports third quarter 2016 financial results (Seattle Genetics Press Release) - "Based on a portfolio review and evaluation of phase 1 clinical data of SGN-CD70A in renal cell carcinoma and CD70-positive non-Hodgkin lymphoma, Seattle Genetics is discontinuing further clinical development of the program."

Discontinued • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma

Seattle Genetics: Annual Report 2014 (Seattle Genetics, Inc) - Anticipated patent expiry in US and Europe between 2024 and 2030; Anticipated patent term extension for certain methods of treatment using SGN-CD70A in US and Europe until 2031

Anticipated patent expiry • Oncology

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. (PubMed, Invest New Drugs) - "SGN-CD70A exposures were approximately dose proportional, with a mean terminal half-life of 3 to 5 days. Conclusions While modest single-agent activity was observed in heavily pretreated NHL patients, the applicability of SGN-CD70A is limited by the frequency and severity of thrombocytopenia, despite the long-term response with limited drug exposure."

Clinical • Journal • P1 data

A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. (PubMed, Cancer) - "The modest antitumor activity of SGN-CD70A does not support its development in mRCC. However, given the high disease control rate in a heavily pretreated population and the modest toxicity profile, CD70 remains of interest because of its immunomodulatory properties."

Clinical • Journal • P1 data